Journal article
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Abstract
BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties …
Authors
Lawlor B; Segurado R; Kennelly S; Rikkert MGMO; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW
Journal
PLOS Medicine, Vol. 15, No. 9,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pmed.1002660
ISSN
1549-1277